T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct

Leukemia

Volumn 27, Issue 5, 2013, Pages 1107-1115

  Aigner, M ^a   Feulner, J ^a   Schaffer, S ^a   Kischel, R ^b   Kufer, P ^b   Schneider, K ^b   Henn, A ^b   Rattel, B ^b   Friedrich, M ^b   Baeuerle, P A ^b   Mackensen, A ^a   Krause, S W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Amgen Research GmbH   (Germany)

Author keywords

acute myeloid leukemia; bispecific antibodies; CD33; cytotoxic T cells; T cell mediated immunity; tumor immunology

Indexed keywords

AMG 330; BISPECIFIC ANTIBODY; CD3 ANTIGEN; CD33 ANTIGEN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLAST CELL; BONE MARROW CELL; CANCER INHIBITION; CELL STRAIN U937; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR GROWTH;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; BLAST CRISIS; CELL MOVEMENT; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, SCID; SIALIC ACID BINDING IG-LIKE LECTIN 3; T-LYMPHOCYTES; U937 CELLS;

EID: 84876116790     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.341     Document Type: Article

References (39)

1. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29: 487-494.
2. Hauswirth AW, Florian S, Printz D, Sotlar K, Krauth MT, Fritsch G et al. Expression of the target receptor CD33 in CD34+/CD38+/CD123+ AML stem cells. Eur J Clin Invest 2007; 37: 73-82.
3. Oka S, Muroi K, Matsuyama T, Sato K, Ueda M, Toshima M et al. Correlation between flow cytometric identification of CD33-positive cells and morphological evaluation of myeloblasts in bone marrow of patients with acute myeloblastic leukemia. Hematology 2009; 14: 133-138.
4. Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 2011; 17: 6417-6427.
5. Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie J et al. Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50-70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA) 53rd ASH Annual Meeting and Exposition San Diego Convention Center 2011.
6. Burnett A, Hills R, Hunter A, Milligan D, Kell W, Wheatley K et al. The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial 53rd ASH Annual Meeting and Exposition. San Diego Conference Center 2011.
7. Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O'Connor J et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 2005; 23: 4110-4116.
8. Lapusan S, Vidriales MB, Thomas X, de Botton S, Vekhoff A, Tang R et al. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs 2012; 30: 1121-1131.
9. Balaian L, Ball ED. Inhibition of acute myeloid leukemia cell growth by mono-specific and bi-specific anti-CD33 x anti-CD64 antibodies. Leuk Res 2004; 28: 821-829.
10. Kugler M, Stein C, Kellner C, Mentz K, Saul D, Schwenkert M et al. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br J Haematol 2010; 150: 574-586.
11. Singer H, Kellner C, Lanig H, Aigner M, Stockmeyer B, Oduncu F et al. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16. J Immunother 2010; 33: 599-608.
12. Lapusan S, Vidriales MB, Thomas X, de Botton S, Vekhoff A, Tang R et al. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs Apr 2012; 30: 1121-1131.
13. Handgretinger R, Zugmaier G, Henze G, Kreyenberg H, Lang P, von Stackelberg A. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 2010; 25: 181-184.
14. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974-977.
15. Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM. SAR3419: an anticd19- maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res 2011; 17: 6448-6458.
16. Bluemel C, Hausmann S, Fluhr P, Sriskandarajah M, Stallcup WB, Baeuerle PA et al. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother 2010; 59: 1197-1209.
17. Haas C, Krinner E, Brischwein K, Hoffmann P, Lutterbuse R, Schlereth B et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 2009; 214: 441-453.
18. Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S, Rattel B et al. T cellengaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAFmutated colorectal cancer cells. Proc Natl Acad Sci USA 2010; 107: 12605-12610.
19. Hoves S, Aigner M, Pfeiffer C, Laumer M, Obermann EC, Mackensen A. In situ analysis of the antigen-processing machinery in acute myeloid leukaemic blasts by tissue microarray. Leukemia 2009; 23: 877-885.
20. van Luijn MM, van den Ancker W, Chamuleau ME, Ossenkoppele GJ, van Ham SM, van de Loosdrecht AA. Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia. Immunotherapy 2010; 2: 85-97.
21. Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000; 95: 2098-2103.
22. Buchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Muller-Tidow C et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009; 27: 61-69.
23. Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. Br J Haematol 2011; 152: 524-542.
24. Felzmann T, Witt V, Wimmer D, Ressmann G, Wagner D, Paul P et al. Monocyte enrichment from leukapharesis products for the generation of DCs by plastic adherence, or by positive or negative selection. Cytotherapy 2003; 5: 391-398.
25. Ersvaer E, Hampson P, Wendelbo O, Lord JM, Gjertsen BT, Bruserud O. Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex. Hematology 2007; 12: 199-207.
26. Le Dieu R, Taussig DC, Ramsay AG, Mitter R, Miraki-Moud F, Fatah R et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood 2009; 114: 3909-3916.
27. Wendelbo O, Nesthus I, Sjo M, Paulsen K, Ernst P, Bruserud O. Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia. Cancer Immunol Immunother 2004; 53: 740-747.
28. Zhou Q, Munger ME, Highfill SL, Tolar J, Weigel BJ, Riddle M et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood 2010; 116: 2484-2493.
29. De Propris MS, Raponi S, Diverio D, Milani ML, Meloni G, Falini B et al. High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation. Haematologica 2011; 96: 1548-1551.
30. Jilani I, Estey E, Huh Y, Joe Y, Manshouri T, Yared M et al. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol 2002; 118: 560-566.
31. Walter RB, Raden BW, Kamikura DM, Cooper JA, Bernstein ID. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin- induced cytotoxicity. Blood 2005; 105: 1295-1302.
32. Taussig DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, Kelly G et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005; 106: 4086-4092.
33. Milani C, Castillo J. Veltuzumab: an anti-CD20 mAb for the treatment of non- Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Curr Opin Mol Ther 2009; 11: 200-207.
34. Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody-constructs of the BiTE class. J Immunother 2007; 30: 798-807.
35. Kellner C, Bruenke J, Stieglmaier J, Schwemmlein M, Schwenkert M, Singer H et al. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. J Immunother 2008; 31: 871-884.
36. Molhoj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P et al. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Mol Immunol 2007; 44: 1935-1943.
37. Choi BD, Cai M, Bigner DD, Mehta AI, Kuan CT, Sampson JH. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin Biol Ther 2011; 11: 843-853.
38. Schubert I, Kellner C, Stein C, Kugler M, Schwenkert M, Saul D et al. A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting. MAbs 2011; 3: 21-30.
39. Stamova S, Cartellieri M, Feldmann A, Bippes CC, Bartsch H, Wehner R et al. Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells. Leukemia 2011; 25: 1053-1056.